Vivos Therapeutics, Inc.VVOSNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank17
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P17
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
2024-21.08%
2023-27.73%
20229.70%
202170.30%
2020-0.43%
201977.11%
20180.00%